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S U M M A R Y
Chagas disease is a complex zoonotic pathology caused by the kinetoplastid Trypanosoma cruzi. This
parasite presents remarkable genetic variability and has been grouped into six discrete typing units
(DTUs). The association between the DTUs and clinical outcome remains unknown. Chagas disease and
co-infection with HIV/AIDS has been reported widely in Brazil and Argentina. Herein, we present the
molecular analyses from a Chagas disease patient with HIV/AIDS co-infection in Colombia who
presented severe cardiomyopathy, pleural effusion, and central nervous system involvement. A mixed
infection by T. cruzi genotypes was detected. We suggest including T. cruzi in the list of opportunistic
pathogens for the management of HIV patients in Colombia. The epidemiological implications of this
ﬁnding are discussed.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Chagas disease is a complex zoonosis caused by the protozoan
Trypanosoma cruzi. This pathology is considered a public health
problem in South America where 7.7 to 10 million people are
infected. Currently, Chagas disease is expanding to other con-
tinents, such as Australia, Europe, and North America, and is
becoming a serious issue in non-endemic countries.1 The co-
infection of Chagas disease and HIV/AIDS has been documented
widely. Most co-infected patients acquire T. cruzi through the
vector-borne route in childhood and acquire HIV later in life. It is
estimated that 98% of co-infection cases are diagnosed in the
chronic stage of the disease, in a context of reactivation, while the
remaining 2% are associated with acute infection.2 According to
previous studies, the most important clinical manifestations of
Chagas disease with HIV/AIDS are associated with the central
nervous system (CNS) (74.2% of cases), probably as result of
severe immunosuppression that gives rise to the primary
clinical manifestation of meningoencephalitis. A second
category of clinical manifestations is associated with chagasic* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).cardiomyopathy, which is more rare (16.7% of cases) and generally
gives rise to the clinical manifestations of heart failure and
arrhythmia.2
T. cruzi displays a relevant genetic variability demonstrated by
at least six discrete typing units (DTUs) from TcI to TcVI.3 Evidence
of the impact of this genetic variability on HIV co-infection is
scarce. However, some studies have suggested a differential tissue
tropism of the infecting DTUs; these studies have reported mixed
infections in co-infected patients, observing TcI and TcII, or TcI,
TcV, and TcVI in blood, and only monoclonal TcI in cerebrospinal
ﬂuid (CSF) or brain tissue.4 Herein, we detected and typed T. cruzi
DTUs from heart and brain tissue of a Chagas disease patient
with HIV/AIDS co-infection who presented severe cardiomyopathy
and encephalopathy.
2. Case report
A 34-year-old female with an HIV infection (conﬁrmed by
Western blot) who was not receiving antiretroviral treatment, was
hospitalized in March 2012. The patient reported having experi-
enced 25 days of evolving chest pain associated with dyspnea,
weight loss, asthenia, adynamia, and hyporexia. An electrocardio-
gram showed signs of systolic left ventricular overload. An
echocardiogram showed moderate mitral and tricuspid regurgita-
tion, ejection fraction <15%, and bilateral pleural effusion. A rapidciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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conducted for Chagas disease and a serological test for hepatitis B.
Both tests returned negative results. She presented neurological
impairment due to sleepiness and a slow response to stimuli. Brain
tomography showed a bifrontal hypodense left lesion and cerebral
edema, and a diagnosis of encephalopathy was made. Consequent-
ly, treatment with sulfadoxine–pyrimethamine for a presumptive
cerebral toxoplasmosis was implemented.
After 8 days of hospitalization, the patient did not show any
improvement. Magnetic resonance imaging (MRI) showed a frontal
lesion of left predominance, with peri-lesional edema causing a
mass effect with a signiﬁcant midline shift that was initially
correlated with lymphoma. Considering that the patient reported
persistent dyspnea, and given the evident extensive pleural
effusion in the right hemithorax, a therapeutic thoracentesis
was performed; only a lymphocyte-predominant exudate was
observed in the pleural ﬂuid. Thereafter, therapy with the broad-
spectrum antibiotic meropenem, 1 g intravenously, was given
every 8 h. Six days later, the patient’s acute condition remained
and her dyspnea had worsened. Antibiotic treatment was
suspended. Afterwards, a decompressive thoracentesis and a
lumbar puncture were performed, and ﬂagellated parasites
consistent with trypomastigotes were observed in both ﬂuids
(pleural and CSF). CSF analysis revealed normal cellularity,
elevated protein (94.05 mg/dl), and low glucose (42.2 mg/dl).
Rapid IgG serological tests with T. cruzi recombinant antigens
(Wiener Laboratorios) were repeated over 3 days. Among the rapid
serological tests, one negative result and two positive results were
obtained. Accordingly, trypanocidal therapy with nifurtimox 8 mg/
kg/day was administered over the course of 4 days following
diagnosis. Unfortunately the patient died 1 day after therapy
ceased.
Pathology, molecular detection, and characterization of T. cruzi
analyses were conducted on post-mortem biopsies from the heart
and brain tissues. Molecular detection using primers 121 and 122Figure 1. Detection and characterization of Trypanosoma cruzi in post-mortem biopsies f
tissues; a T. cruzi amastigote nest is present in the brain tissue (original magniﬁcation 10
Lanes 1–4 are ampliﬁcation products of the intergenic region of the mini-exon: lane 1
(300 bp). Lanes 5–7 are ampliﬁcation products of kDNA: lane 5, heart tissue; lane 6
Electrophoresis on a 2% agarose gel visualized by staining with Gel Red 100-bp weighttargeted to the variable region of kinetoplast DNA was imple-
mented. Moreover, molecular detection of the B1 gene of
Toxoplasma gondii was performed using primers and PCR condi-
tions reported previously, in order to rule out cerebral toxoplas-
mosis. Molecular characterization was conducted using the
intergenic region of the mini-exon gene (SL-IR), the 24Sa and
18S regions of rDNA.4 The results of the PCR conducted in both
tissues were positive for T. cruzi kDNA, revealing a mixed infection
in the heart by TcI and TcII (TcI/TcII), and only TcI in the brain. The
ampliﬁcation products of SL-IR, obtained from heart and brain
tissues, were cloned and sequenced to discriminate TcI genotypes.
A mixed infection by TcI sylvatic-type and TcIDOM genotype was
observed in the heart, while in the brain only TcI sylvatic-type was
detected. To test the integrity of the DNA, we applied b-actin gene
detection, which was positive. Pathology studies were conducted;
myocarditis and pericarditis with a lymphocytic inﬁltrate in the
heart and necrosis with lymphocytic inﬁltrate and numerous
parasites in the brain were observed (Figure 1).
3. Discussion
Even considering the acute clinical manifestations, the case
reported possibly represents a reactivation of Chagas disease due
to co-infection with HIV/AIDS. The history of living in an endemic
area is the main epidemiological criterion for suspecting T. cruzi
infection.5 The patient was born and had lived in the municipality
of Cesar, where Chagas disease cases and the presence of
triatomines such as Rhodnius prolixus, Panstrongylus geniculatus,
Eratyrus cuspidatus, and Belminus herreri, have been reported
previously. Consequently, she may have acquired the T. cruzi
infection through the vector-borne route during childhood and the
HIV infection later in life.
During hospitalization, the patient showed negative serology to
Chagas disease and a necrotic lesion suggestive of neurotoxo-
plasmosis in the brain. The suspicion of neurotoxoplasmosis led torom heart and brain tissues. (A) Hematoxylin and eosin stained sections from brain
0). (B) PCR ampliﬁcation of DNA and characterization from T. cruzi present in tissues.
, heart tissue; lane 2, brain tissue; lane 3, TcI control (350 bp); lane 4, TcII control
, brain tissue; lane 7, TcI control (330 bp). Lanes 8 and 9 are negative controls.
 marker.
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treatment. The alterations caused by T. cruzi in the brains of Chagas
and HIV/AIDS co-infected patients show focal necrotic lesions
indistinguishable from those caused by T. gondii. Consequently,
these patients are frequently treated for cerebral toxoplasmosis,
increasing mortality because of the delay in appropriate treat-
ment.2 In our case, T. gondii infection was excluded by a nested and
sensitive PCR assay.
Worldwide, the major parasitic diseases considered as
opportunistic infections for HIV/AIDS are toxoplasmosis, crypto-
sporidiosis, and cystoisosporiasis. In addition, several countries
endemic for Chagas disease, including Brazil, Chile, and Argentina,
have included T. cruzi on the list of opportunistic pathogens.
However, in Colombia, despite reported cases, T. cruzi has not been
included as an opportunistic pathogen in the protocols for the
management of HIV/AIDS. It is noteworthy that timely speciﬁc
therapy with benznidazole and nifurtimox has proven to be highly
effective in cases of reactivation of Chagas disease, even if this
treatment has not been formally incorporated into the manage-
ment protocols for immunocompromised patients. It is even
recommended that the speciﬁc therapy should be started before
immunosuppression whenever possible to reduce the risk of
reactivation.
We have described the molecular characterization of T. cruzi in a
patient with HIV co-infection in Colombia. The ﬁndings highlight
the usefulness of PCR as a complementary tool for the rapid,
differential, and sensitive diagnosis of Chagas disease in HIV/AIDS
patients. Lastly, the presence of mixed infection by TcI/TcII in the
heart and TcI sylvatic-type in the brain, and the epidemiological
data, suggest that the severity of symptoms should be attributed to
co-infection by TcI genotypes associated with domestic andsylvatic cycles. These may show neurotropism and high pathoge-
nicity in cardiac tissue resulting from a state of immunosuppres-
sion caused by HIV infection. This information is of paramount
importance to understand the tissue tropism of T. cruzi DTUs and
its possible relationship with the clinical manifestations of the
disease.
Acknowledgements
This work was supported by Departamento Administrativo
Nacional de Ciencia y Tecnologı´a de Colombia ‘‘Francisco Jose´ de
Caldas – COLCIENCIAS’’ and ‘‘Unio´n Temporal Programa Nacional
de Investigacio´n para la prevencio´n, control y tratamiento integral
de la enfermedad de Chagas en Colombia’’, grant number 380-
2011, code 5014-537-30398.
Conﬂict of interest: We declare no conﬂicts of interest.
References
1. PAHO/WHO (Organizacio´n Panamericana de la Salud; OPS/OMS). Estimacio´n
cuantitativa de la Enfermedad de Chagas en las Ame´ricas. OPS/HDM/CD/425-06.
Montevideo, Uruguay; 2006.
2. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis
2012;25:450–7.
3. Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM,
et al. The revised Trypanosoma cruzi subspeciﬁc nomenclature: rationale,
epidemiological relevance and research applications. Infect Genet Evol
2012;12:240–53.
4. Burgos JM, Begher S, Silva HM, Bisio M, Duffy T, Levin MJ, et al. Molecular
identiﬁcation of Trypanosoma cruzi I tropism for central nervous system in
Chagas reactivation due to AIDS. Am J Trop Med Hyg 2008;78:294–7.
5. Diaz-Granados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire
C, Franco-Paredes C. Chagasic encephalitis in HIV patients: common presenta-
tion of an evolving epidemiological and clinical association. Lancet Infect Dis
2009;9:324–30.
